Resistance-fighting antimalarial drug candidate enters the clinic

A new antimalarial drug candidate, discovered through a longstanding collaboration between WEHI and global biopharmaceutical company MSD has entered Phase 1 clinical testing in healthy participants. The candidate drug inhibits two essential enzymes required for the growth of malaria parasites and the spread of the disease through human-to-mosquito transmission.